Moody's Ratings (Moody's) assigned Aaa ratings to the new USD and EUR denominated senior unsecured note offerings of Johnson & Johnson ("J&J"). There are no changes to J&J's existing ratings including the Aaa senior unsecured long-term rating or the Prime-1 short-term rating. The outlook remains unc...
Shockwave Medical Reports First Quarter 2024 Financial Results SANTA CLARA, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months ended March 31, 2024. “The solid growth in the first quarter across geographies and products is a testament to the continued demand for our innovative solutions, driven by the unrelenting and extraordinary performance of our global Shockwave teams,” said...
Shockwave Reducer Demonstrates Consistent, Positive Results in ‘Real-World’ Study Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina SANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results to three...
Moody's Ratings (Moody's) affirmed the ratings of Johnson & Johnson ("J&J") including the Aaa long-term issuer rating, Aaa senior unsecured rating, (P)Aaa senior unsecured medium term note program rating and Prime-1 commercial paper rating. The outlook remains stable. This rating action follows th...
Shockwave Medical to Participate in the 23rd Annual Needham Virtual Healthcare Conference SANTA CLARA, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that the company will be participating in the 23rd Annual Needham Virtual Healthcare Conference, which is being held virtually from Monday, April 8 to Thursday, April 11, 2024. Shockwave’s management is scheduled for a live fireside chat on Tuesday, April 9, 20...
A director at Johnson & Johnson sold 8,891 shares at 162.160USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Shockwave Medical Reports Fourth Quarter and Full Year 2023 Financial Results SANTA CLARA, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2023. Recent Highlights Recognized revenue of $203.0 million for the fourth quarter of 2023 and $730.2 million for the full year 2023, representing increases of 41% and 49%, respectively, from the sam...
Summary Saponia dd - Company Profile and SWOT Analysis, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Saponia dd (Saponia) is a manufacturer of home care and personal hygiene products. The company’s product portfolio comprises dish detergents, laundry detergents, toothbrushes, baby care, hand cream, shaving ...
Shockwave Medical Appoints Renee Gaeta as Chief Financial Officer SANTA CLARA, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today the appointment of Renee Gaeta as Chief Financial Officer (CFO), effective February 5, 2024. Renee succeeds Dan Puckett, CFO at Shockwave since 2016, who previously announced his decision to retire. “Renee is a highly skilled and accomplished executive with a proven track record in the m...
Shockwave Medical Provides Quarterly Earnings Release Dates for 2024 SANTA CLARA, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- January 8, 2024 – Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, announced today that it expects to issue quarterly earnings releases after the market closes and hold conference calls at the times indicated on the following dates: Fourth Quarter 2023 Earnings – Thursday, February 15, 2024 at 4:30 p.m. (ET)First Quarter 2024 Earnings – Monday, May...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.